Group 4 ITI Consensus Report: Risks and biologic complications associated with implant dentistry

Lisa J. Heitz-Mayfield, Merete Aaboe, Mauricio Araujo, Juan B. Carrión, Raffaele Cavalcanti, Norbert Cionca, David L Cochran, Ivan Darby, Eiji Funakoshi, Petra C. Gierthmuehlen, Dena Hashim, Leila Jahangiri, Yongdae Kwon, France Lambert, Danielle M. Layton, Eduardo R. Lorenzana, Gerald McKenna, Andrea Mombelli, Frauke Müller, Mario RoccuzzoGiovanni E. Salvi, Martin Schimmel, Murali Srinivasan, Cristiano Tomasi, Alvin Yeo

Research output: Contribution to journalReview article

Abstract

Objectives: The aim of Working Group 4 was to address topics related to biologic risks and complications associated with implant dentistry. Focused questions on (a) diagnosis of peri-implantitis, (b) complications associated with implants in augmented sites, (c) outcomes following treatment of peri-implantitis, and (d) implant therapy in geriatric patients and/or patients with systemic diseases were addressed. Materials and methods: Four systematic reviews formed the basis for discussion in Group 4. Participants developed statements and recommendations determined by group consensus based on the findings of the systematic reviews. These were then presented and accepted following further discussion and modifications as required by the plenary. Results: Bleeding on probing (BOP) alone is insufficient for the diagnosis of peri-implantitis. The positive predictive value of BOP alone for the diagnosis of peri-implantitis varies and is dependent on the prevalence of peri-implantitis within the population. For patients with implants in augmented sites, the prevalence of peri-implantitis and implant loss is low over the medium to long term. Peri-implantitis treatment protocols which include individualized supportive care result in high survival of implants after 5 years with about three-quarters of implants still present. Advanced age alone is not a contraindication for implant therapy. Implant placement in patients with cancer receiving high-dose antiresorptive therapy is contraindicated due to the associated high risk for complications. Conclusions: Diagnosis of peri-implantitis requires the presence of BOP as well as progressive bone loss. Prevalence of peri-implantitis for implants in augmented sites is low. Peri-implantitis treatment should be followed by individualized supportive care. Implant therapy for geriatric patients is not contraindicated; however, comorbidities and autonomy should be considered.

Original languageEnglish (US)
Pages (from-to)351-358
Number of pages8
JournalClinical Oral Implants Research
Volume29
DOIs
StatePublished - Oct 1 2018

Fingerprint

Peri-Implantitis
Dentistry
Hemorrhage
Geriatrics
Therapeutics
Clinical Protocols
Comorbidity

Keywords

  • augmentation
  • complication
  • geriatric
  • implant survival
  • peri-implantitis
  • supportive care
  • systemic conditions

ASJC Scopus subject areas

  • Oral Surgery

Cite this

Heitz-Mayfield, L. J., Aaboe, M., Araujo, M., Carrión, J. B., Cavalcanti, R., Cionca, N., ... Yeo, A. (2018). Group 4 ITI Consensus Report: Risks and biologic complications associated with implant dentistry. Clinical Oral Implants Research, 29, 351-358. https://doi.org/10.1111/clr.13307

Group 4 ITI Consensus Report : Risks and biologic complications associated with implant dentistry. / Heitz-Mayfield, Lisa J.; Aaboe, Merete; Araujo, Mauricio; Carrión, Juan B.; Cavalcanti, Raffaele; Cionca, Norbert; Cochran, David L; Darby, Ivan; Funakoshi, Eiji; Gierthmuehlen, Petra C.; Hashim, Dena; Jahangiri, Leila; Kwon, Yongdae; Lambert, France; Layton, Danielle M.; Lorenzana, Eduardo R.; McKenna, Gerald; Mombelli, Andrea; Müller, Frauke; Roccuzzo, Mario; Salvi, Giovanni E.; Schimmel, Martin; Srinivasan, Murali; Tomasi, Cristiano; Yeo, Alvin.

In: Clinical Oral Implants Research, Vol. 29, 01.10.2018, p. 351-358.

Research output: Contribution to journalReview article

Heitz-Mayfield, LJ, Aaboe, M, Araujo, M, Carrión, JB, Cavalcanti, R, Cionca, N, Cochran, DL, Darby, I, Funakoshi, E, Gierthmuehlen, PC, Hashim, D, Jahangiri, L, Kwon, Y, Lambert, F, Layton, DM, Lorenzana, ER, McKenna, G, Mombelli, A, Müller, F, Roccuzzo, M, Salvi, GE, Schimmel, M, Srinivasan, M, Tomasi, C & Yeo, A 2018, 'Group 4 ITI Consensus Report: Risks and biologic complications associated with implant dentistry', Clinical Oral Implants Research, vol. 29, pp. 351-358. https://doi.org/10.1111/clr.13307
Heitz-Mayfield LJ, Aaboe M, Araujo M, Carrión JB, Cavalcanti R, Cionca N et al. Group 4 ITI Consensus Report: Risks and biologic complications associated with implant dentistry. Clinical Oral Implants Research. 2018 Oct 1;29:351-358. https://doi.org/10.1111/clr.13307
Heitz-Mayfield, Lisa J. ; Aaboe, Merete ; Araujo, Mauricio ; Carrión, Juan B. ; Cavalcanti, Raffaele ; Cionca, Norbert ; Cochran, David L ; Darby, Ivan ; Funakoshi, Eiji ; Gierthmuehlen, Petra C. ; Hashim, Dena ; Jahangiri, Leila ; Kwon, Yongdae ; Lambert, France ; Layton, Danielle M. ; Lorenzana, Eduardo R. ; McKenna, Gerald ; Mombelli, Andrea ; Müller, Frauke ; Roccuzzo, Mario ; Salvi, Giovanni E. ; Schimmel, Martin ; Srinivasan, Murali ; Tomasi, Cristiano ; Yeo, Alvin. / Group 4 ITI Consensus Report : Risks and biologic complications associated with implant dentistry. In: Clinical Oral Implants Research. 2018 ; Vol. 29. pp. 351-358.
@article{25e8c562e49a4b04854345b3f98d8e18,
title = "Group 4 ITI Consensus Report: Risks and biologic complications associated with implant dentistry",
abstract = "Objectives: The aim of Working Group 4 was to address topics related to biologic risks and complications associated with implant dentistry. Focused questions on (a) diagnosis of peri-implantitis, (b) complications associated with implants in augmented sites, (c) outcomes following treatment of peri-implantitis, and (d) implant therapy in geriatric patients and/or patients with systemic diseases were addressed. Materials and methods: Four systematic reviews formed the basis for discussion in Group 4. Participants developed statements and recommendations determined by group consensus based on the findings of the systematic reviews. These were then presented and accepted following further discussion and modifications as required by the plenary. Results: Bleeding on probing (BOP) alone is insufficient for the diagnosis of peri-implantitis. The positive predictive value of BOP alone for the diagnosis of peri-implantitis varies and is dependent on the prevalence of peri-implantitis within the population. For patients with implants in augmented sites, the prevalence of peri-implantitis and implant loss is low over the medium to long term. Peri-implantitis treatment protocols which include individualized supportive care result in high survival of implants after 5 years with about three-quarters of implants still present. Advanced age alone is not a contraindication for implant therapy. Implant placement in patients with cancer receiving high-dose antiresorptive therapy is contraindicated due to the associated high risk for complications. Conclusions: Diagnosis of peri-implantitis requires the presence of BOP as well as progressive bone loss. Prevalence of peri-implantitis for implants in augmented sites is low. Peri-implantitis treatment should be followed by individualized supportive care. Implant therapy for geriatric patients is not contraindicated; however, comorbidities and autonomy should be considered.",
keywords = "augmentation, complication, geriatric, implant survival, peri-implantitis, supportive care, systemic conditions",
author = "Heitz-Mayfield, {Lisa J.} and Merete Aaboe and Mauricio Araujo and Carri{\'o}n, {Juan B.} and Raffaele Cavalcanti and Norbert Cionca and Cochran, {David L} and Ivan Darby and Eiji Funakoshi and Gierthmuehlen, {Petra C.} and Dena Hashim and Leila Jahangiri and Yongdae Kwon and France Lambert and Layton, {Danielle M.} and Lorenzana, {Eduardo R.} and Gerald McKenna and Andrea Mombelli and Frauke M{\"u}ller and Mario Roccuzzo and Salvi, {Giovanni E.} and Martin Schimmel and Murali Srinivasan and Cristiano Tomasi and Alvin Yeo",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/clr.13307",
language = "English (US)",
volume = "29",
pages = "351--358",
journal = "Clinical Oral Implants Research",
issn = "0905-7161",
publisher = "Blackwell Munksgaard",

}

TY - JOUR

T1 - Group 4 ITI Consensus Report

T2 - Risks and biologic complications associated with implant dentistry

AU - Heitz-Mayfield, Lisa J.

AU - Aaboe, Merete

AU - Araujo, Mauricio

AU - Carrión, Juan B.

AU - Cavalcanti, Raffaele

AU - Cionca, Norbert

AU - Cochran, David L

AU - Darby, Ivan

AU - Funakoshi, Eiji

AU - Gierthmuehlen, Petra C.

AU - Hashim, Dena

AU - Jahangiri, Leila

AU - Kwon, Yongdae

AU - Lambert, France

AU - Layton, Danielle M.

AU - Lorenzana, Eduardo R.

AU - McKenna, Gerald

AU - Mombelli, Andrea

AU - Müller, Frauke

AU - Roccuzzo, Mario

AU - Salvi, Giovanni E.

AU - Schimmel, Martin

AU - Srinivasan, Murali

AU - Tomasi, Cristiano

AU - Yeo, Alvin

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Objectives: The aim of Working Group 4 was to address topics related to biologic risks and complications associated with implant dentistry. Focused questions on (a) diagnosis of peri-implantitis, (b) complications associated with implants in augmented sites, (c) outcomes following treatment of peri-implantitis, and (d) implant therapy in geriatric patients and/or patients with systemic diseases were addressed. Materials and methods: Four systematic reviews formed the basis for discussion in Group 4. Participants developed statements and recommendations determined by group consensus based on the findings of the systematic reviews. These were then presented and accepted following further discussion and modifications as required by the plenary. Results: Bleeding on probing (BOP) alone is insufficient for the diagnosis of peri-implantitis. The positive predictive value of BOP alone for the diagnosis of peri-implantitis varies and is dependent on the prevalence of peri-implantitis within the population. For patients with implants in augmented sites, the prevalence of peri-implantitis and implant loss is low over the medium to long term. Peri-implantitis treatment protocols which include individualized supportive care result in high survival of implants after 5 years with about three-quarters of implants still present. Advanced age alone is not a contraindication for implant therapy. Implant placement in patients with cancer receiving high-dose antiresorptive therapy is contraindicated due to the associated high risk for complications. Conclusions: Diagnosis of peri-implantitis requires the presence of BOP as well as progressive bone loss. Prevalence of peri-implantitis for implants in augmented sites is low. Peri-implantitis treatment should be followed by individualized supportive care. Implant therapy for geriatric patients is not contraindicated; however, comorbidities and autonomy should be considered.

AB - Objectives: The aim of Working Group 4 was to address topics related to biologic risks and complications associated with implant dentistry. Focused questions on (a) diagnosis of peri-implantitis, (b) complications associated with implants in augmented sites, (c) outcomes following treatment of peri-implantitis, and (d) implant therapy in geriatric patients and/or patients with systemic diseases were addressed. Materials and methods: Four systematic reviews formed the basis for discussion in Group 4. Participants developed statements and recommendations determined by group consensus based on the findings of the systematic reviews. These were then presented and accepted following further discussion and modifications as required by the plenary. Results: Bleeding on probing (BOP) alone is insufficient for the diagnosis of peri-implantitis. The positive predictive value of BOP alone for the diagnosis of peri-implantitis varies and is dependent on the prevalence of peri-implantitis within the population. For patients with implants in augmented sites, the prevalence of peri-implantitis and implant loss is low over the medium to long term. Peri-implantitis treatment protocols which include individualized supportive care result in high survival of implants after 5 years with about three-quarters of implants still present. Advanced age alone is not a contraindication for implant therapy. Implant placement in patients with cancer receiving high-dose antiresorptive therapy is contraindicated due to the associated high risk for complications. Conclusions: Diagnosis of peri-implantitis requires the presence of BOP as well as progressive bone loss. Prevalence of peri-implantitis for implants in augmented sites is low. Peri-implantitis treatment should be followed by individualized supportive care. Implant therapy for geriatric patients is not contraindicated; however, comorbidities and autonomy should be considered.

KW - augmentation

KW - complication

KW - geriatric

KW - implant survival

KW - peri-implantitis

KW - supportive care

KW - systemic conditions

UR - http://www.scopus.com/inward/record.url?scp=85055023401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055023401&partnerID=8YFLogxK

U2 - 10.1111/clr.13307

DO - 10.1111/clr.13307

M3 - Review article

C2 - 30328181

AN - SCOPUS:85055023401

VL - 29

SP - 351

EP - 358

JO - Clinical Oral Implants Research

JF - Clinical Oral Implants Research

SN - 0905-7161

ER -